Clinical Trial Update: Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CAOP (Aclarubicin, Cyclophosphamide, Vincristine, Prednisone) for previously untreated peripheral T-cell lymphoma. The study is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma Alk-negative
• Nodal T-follicular Helper Cell Lymphoma
• Peripheral T-cell Lymphoma Not Otherwise Specified

Drugs mentioned

• Aclarubicin (aclarubicin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING